✓
Open
16 Dec 2021
✓
Close
20 Dec 2021
3
Allotment
—
✓
Listing
Tue, Dec 28, 2021
Price Band
₹265 to ₹274
Issue Size
2,55,47,445 shares (agg. up to ₹700 Cr)
Lot Size
54 Shares
Listing Date
Tue, Dec 28, 2021
Latest GMP
₹130
Est. Gain
47.45%
✦ AI Insight
GMP Trend
28-12-2021₹130Est. ₹404+47.45%
26-12-2021₹130Est. ₹404+47.45%
25-12-2021₹120Est. ₹394+43.8%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 39.68x |
Restated Financials (₹ Cr.)
| Period Ended | 30 Sep 2021 | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 |
|---|---|---|---|---|
| Assets | 504.10 | 445.82 | 336.43 | 253.05 |
| Total Income | 230.06 | 396.22 | 322.71 | 285.86 |
| Profit After Tax | 65.96 | 123.83 | 73.40 | 39.42 |
| EBITDA | 98.67 | 178.15 | 109.45 | 72.76 |
| NET Worth | 93.79 | 149.19 | 268.94 | 334.86 |
| Reserves and Surplus | 320.23 | 254.31 | 134.56 | 79.15 |
| Total Borrowing | 70.99 | 70.13 | 82.21 | 89.84 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Sigachi Industries Ltd. | Mainboard | ₹125.43 Cr | ₹163 | null | ₹598.50 | +267.18% | ₹24.53 (+2.00%) |
| Ami Organics Ltd. | Mainboard | ₹569.64 Cr | ₹610 | null | ₹935.00 | +53.28% | ₹3,583.80 (+1.01%) |
| Windlas Biotech Ltd. | Mainboard | ₹401.54 Cr | ₹460 | null | ₹407.15 | -11.49% | ₹850.25 (+1.16%) |
| Glenmark Life Sciences Ltd. | Mainboard | ₹1,513.60 Cr | ₹720 | null | ₹748.50 | +3.96% | ₹1,164.10 (-0.31%) |
| Walpar Nutritions Ltd. | SME | ₹6.60 Cr | ₹55 | null | ₹57.00 | +3.64% | ₹34.50 (+0.00%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirements of the Company; | 92.30 |
| 2 | Repayment and/ or pre-payment, in full or part, of certain borrowings availed by the Company | 60.00 |
| 3 | General corporate purposes. | 35.95 |
About Supriya Lifescience IPO
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. The company is also one of the largest exporters of Salbutamol Sulphate from India in FY 2021 in terms of volume. In Fiscal 2021, the company's products were exported to 86 countries to 1,296 customers including 346 distributors. The company has API business in Europe, Latin America, Asia, and North America. Supriya Lifescience has a modern manufacturing facility in Maharashtra spread across 23,806 sq. mts, having a reactor capacity of 547 KL/ day including 7 clean rooms. The company has also acquired a plot of land, admeasuring 12,551 sq. mt, near the present manufacturing facility, to expand its manufacturing infrastructure. The company's manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)-
Contact Details
Supriya Lifescience Ltd. Address207/208, Udyog BhavanSonawala RoadGoregaon (East)Mumbai, Maharashtra, 400063+91-22-40332727cs@supriyalifescience.comVisit Website